论文部分内容阅读
多相分散系药物制剂包括各种混悬剂、乳剂、脂质体及多相脂质体等。无论脂质体、乳剂或其他微粒分散体系用于静脉注射给药剂型时,其粒度是一项需要严格控制的指标。英国药典(1980年)规定,用于静注的乳剂粒子直径应<5μm。中国药典(1985年版)对混悬型注射液规定粒度<15μm。药物的分散状态和分散程度不同,所表现的作用以及体内过程也不尽相同。脂质体的粒度分布是其在血液循环系统中消除、各组织的吸收、组织间转移、细胞吞噬和融合以及细胞间相互作用的特别重要的参数。由此可见,
Heterogeneous dispersion drug formulations include various suspensions, emulsions, liposomes and multi-phase liposomes and the like. Whether liposomes, emulsions or other microparticle dispersions are used for intravenous administration, their particle size is an indicator that needs to be tightly controlled. The British Pharmacopoeia (1980) states that emulsion particles used for intravenous use should be <5 μm in diameter. Chinese Pharmacopoeia (1985 edition) for suspension injection size requirements of <15μm. Differences in the degree of dispersion and dispersion of drugs, the role of performance and in vivo processes are not the same. The particle size distribution of liposomes is a particularly important parameter of its elimination in the blood circulatory system, absorption of tissues, inter-tissue metastases, phagocytosis and fusion of cells, and cell-cell interactions. Thus,